EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Association of baseline plasma NMDA receptor–related amino acid ratios with remission following antidepressant treatment in major depressive disorder

Yuji Murase, Haruhiko Ogata, Yutaro Shimamoto, Toshiya Funatsuki, Yosuke Koshikawa, Yoshiteru Takekita, Kenji Hashimoto, Masaki Kato

Journal of Affective Disorders · 2026-12 · 414 · 122231

DOI: 10.1016/j.jad.2026.122231 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Affective Disorders, 2026-12. Verfasst von Yuji Murase und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Faculty of Medicine, Kansai Medical University, Osaka, Japan; Social Welfare Corporation Seishokai Sephiroth Hospital,…. Hauptthemen laut MEDLINE: Major Depressive Disorder, Receptors, N-Methyl-D-Aspartate, Antidepressive Agents, Amino Acids. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Senshin Medical Research Foundation, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The contribution of glutamatergic and neuroplasticity-related mechanisms to antidepressant efficacy beyond monoaminergic modulation is increasingly recognized. Amino acids related to N-methyl-d-aspartate receptor (NMDAR) function have been implicated in the pathophysiology of depression; however, their relevance to antidepressant treatment outcomes remains unclear. METHODS: In this exploratory pooled analysis, we integrated data from a prospective observational cohort study (REBELLION Study) and an open-label randomized controlled trial (GUNDAM Study). Outpatients with major depressive disorder (MDD) who initiated antidepressant monotherapy were included. Baseline plasma ratios of NMDAR-related amino acids (d-serine/l-serine, l-serine/glycine, and glutamine/glutamate) were examined in relation to remission at week 6 (17-item Hamilton Depression Rating Scale score ≤ 7) using multivariable logistic regression. Exploratory interaction analyses assessed effect modification by antidepressant pharmacological class (mirtazapine vs. non-mirtazapine). RESULTS: Among 91 participants, higher baseline d-serine/l-serine (adjusted odds ratio [aOR] per 10% of the median = 1.18, 95% confidence interval [CI] 1.01-1.38) and glutamine/glutamate (aOR per 10% of the median = 1.06, 95% CI 1.00-1.11) ratios were associated with remission at week 6. Interaction analyses suggested possible antidepressant-class differences, with d-serine/l-serine associated with remission in the non-mirtazapine group and glutamine/glutamate in the mirtazapine group. CONCLUSIONS: Baseline plasma NMDAR-related amino acid ratios were associated with remission following short-term antidepressant treatment in patients with MDD. These exploratory findings suggest that peripheral amino acid profiles may contribute to interindividual variability in antidepressant outcomes. However, they should be interpreted as hypothesis-generating rather than as evidence of biomarker utility, and require replication in independent and longitudinal cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderReceptors, N-Methyl-D-AspartateAntidepressive AgentsAmino AcidsHumansFemaleMaleSerineAdultGlutamic AcidMirtazapineGlutamineMiddle AgedMianserinTreatment OutcomeProspective StudiesRemission InductionGlycine

Stichwörter der Autor:innen

Glutamine/glutamate ratioMajor depressive disorderMirtazapineN-methyl-d-aspartate receptorRemissionSelective serotonin reuptake inhibitorsd-serine/l-serine ratio

Substanzen

Receptors, N-Methyl-D-AspartateAntidepressive AgentsSerineGlutamic AcidMirtazapineGlutamineMianserinAmino AcidsGlycine

Autor:innen und Institutionen

  • Department of Neuropsychiatry, Faculty of Medicine, Kansai Medical University, Osaka, Japan; Social Welfare Corporation Seishokai Sephiroth Hospital, Shiga, Japan.
  • Department of Neuropsychiatry, Faculty of Medicine, Kansai Medical University, Osaka, Japan.
  • Center for Forensic Mental Health, Chiba University, Chiba, Japan.
  • Department of Neuropsychiatry, Faculty of Medicine, Kansai Medical University, Osaka, Japan. Electronic address: katou.mas@kmu.ac.jp.

Förderung

  • Senshin Medical Research Foundation
  • Japan Society for the Promotion of Science

Zitieren

APA

Murase, Y., Ogata, H., Shimamoto, Y., Funatsuki, T., Koshikawa, Y., Takekita, Y., Hashimoto, K., & Kato, M. (2026). Association of baseline plasma NMDA receptor–related amino acid ratios with remission following antidepressant treatment in major depressive disorder. Journal of Affective Disorders, 414, 122231. https://doi.org/10.1016/j.jad.2026.122231

Vancouver

Murase Y, Ogata H, Shimamoto Y, Funatsuki T, Koshikawa Y, Takekita Y, et al. Association of baseline plasma NMDA receptor–related amino acid ratios with remission following antidepressant treatment in major depressive disorder. Journal of Affective Disorders. 2026;414:122231. doi:10.1016/j.jad.2026.122231

BibTeX
@article{Murase2026,
  author = {Murase, Yuji and Ogata, Haruhiko and Shimamoto, Yutaro and Funatsuki, Toshiya and Koshikawa, Yosuke and Takekita, Yoshiteru and Hashimoto, Kenji and Kato, Masaki},
  title = {Association of baseline plasma NMDA receptor–related amino acid ratios with remission following antidepressant treatment in major depressive disorder},
  journal = {Journal of Affective Disorders},
  year = {2026},
  volume = {414},
  pages = {122231},
  doi = {10.1016/j.jad.2026.122231}
}
Kostenlos starten →